Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Asset Writedowns and Impairment (2016 - 2025)

Iradimed (IRMD) has disclosed Asset Writedowns and Impairment for 12 consecutive years, with $19146.0 as the latest value for Q3 2025.

  • On a quarterly basis, Asset Writedowns and Impairment fell 89.57% to $19146.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$87832.0, a 153.67% decrease, with the full-year FY2024 number at $87641.0, down 51.7% from a year prior.
  • Asset Writedowns and Impairment was $19146.0 for Q3 2025 at Iradimed, down from $45239.0 in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $183613.0 in Q3 2024 to a low of -$114499.0 in Q4 2024.
  • A 5-year average of $24721.3 and a median of $19146.0 in 2025 define the central range for Asset Writedowns and Impairment.
  • Peak YoY movement for Asset Writedowns and Impairment: soared 5117.81% in 2021, then tumbled 10001.05% in 2023.
  • Iradimed's Asset Writedowns and Impairment stood at $66486.0 in 2021, then tumbled by 100.57% to -$381.0 in 2022, then crashed by 10001.05% to -$38485.0 in 2023, then tumbled by 197.52% to -$114499.0 in 2024, then surged by 116.72% to $19146.0 in 2025.
  • Per Business Quant, the three most recent readings for IRMD's Asset Writedowns and Impairment are $19146.0 (Q3 2025), $45239.0 (Q2 2025), and -$37718.0 (Q1 2025).